Clinical Trial Update: Phase 3 Study - Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI) [Phase 3]

View source ↗

Summary

Phase 3 study of PTK 0796 (omadacycline) for complicated skin and soft tissue infections has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Complicated Skin and Soft Tissue Infections

Drugs mentioned

• Omadacycline (PTK 0796) (omadacycline)

Snippet

Sponsor: Paratek Pharmaceuticals Inc | Conditions: Skin Structures and Soft Tissue Infections | Phase 3 | Status: WITHDRAWN